



# Scientometric Analysis and Mapping of Scientific Articles on Diabetic Retinopathy

Shahrokh RAMIN MD<sup>1</sup>, Reza GHAREBAGHI MD<sup>2</sup>, Fatemeh HEIDARY MD FICO<sup>2</sup>

<sup>1</sup>Ophthalmic Research Center, Shahid Beheshti University of Medical Sciences, Tehran, Iran

<sup>2</sup>Health Policy Research Center, Shiraz University of Medical Sciences, Shiraz, Iran

## ABSTRACT

Diabetic retinopathy (DR) is the major cause of blindness among the working-age population globally. No systematic research has been previously performed to analyze the research published on DR, despite the need for it. This study aimed to analyze the scientific production on DR to draw overall roadmap of future research strategic planning in this field. A bibliometric method was used to obtain a view on the scientific production about DR by the data extracted from the Institute for Scientific Information (ISI). Articles about DR published in 1993–2013 were analyzed to obtain a view of the topic's structure, history, and to document relationships. The trends in the most influential publications and authors were analyzed. Most highly cited articles addressed epidemiologic and translational research topics in this field. During the past 3 years, there has been a trend toward biomarker discovery and more molecular translational research. Areas such as gene therapy and micro-RNAs are also among the recent hot topics. Through analyzing the characteristics of papers and the trends in scientific production, we performed the first scientometric report on DR. Most influential articles have addressed epidemiology and translational research subjects in this field, which reflects that globally, the earlier diagnosis and treatment of this devastating disease still has the highest global priority.

## KEY WORDS

Diabetic Retinopathy; Bibliometrics; Historiography; Scientometry; Citation Analysis

©2015, Med Hypothesis Discov Innov Ophthalmol.

This is an open-access article distributed under the terms of the Creative Commons Attribution Non Commercial 3.0 License (CC BY-NC 3.0), which allows users to read, copy, distribute and make derivative works for non-commercial purposes from the material, as long as the author of the original work is cited properly.

## Correspondence to:

Dr Shahrokh Ramin. Ophthalmic Research Center, Shahid Beheshti University of Medical Sciences, Tehran, Iran, Phone: +98 21 22591616, Fax: +98 21 22590607, Email: dr.ramin1346@gmail.com

## INTRODUCTION

An estimated 382 million people had diabetes in 2013; this is expected to rise to 592 million by 2035 (1). Diabetic retinopathy (DR), age-related macular degeneration (ARMD), glaucoma, and childhood causes are the most common causes of low vision in all countries (2). Estimates of the prevalence of DR vary by study and rates range from 17.6% in a study in India to 33.2% in a large United States study (3, 4). There were 126.6 million people with DR worldwide in 2010; this is

expected to increase to 191.0 million by 2030. The number of patients with vision-threatening DR will increase from 37.3 million to 56.3 million (5, 6). If a diabetic patient does not have retinopathy, studies suggest that the risk of developing new retinopathy ranges between 5% and 10% annually. Thus, there is an urgent need for prompt action.

Preventing and treating DR are major concerns in this field. If fundamental social and political changes are available, the prevention of diabetes would be the best



approach to prevent DR. Factors which lower the risk of visual morbidities and disease progression in diabetic patients include optimal blood glucose and blood pressure control beside regular ocular examinations and prompt laser treatment of macular edema as well as proliferative retinopathy. The Wisconsin Epidemiologic Study of Diabetic Retinopathy (i.e., WESDR) first identified key risk factors for DR such as longer duration of diabetes, hyperglycemia, and hypertension (7, 8). Based on the finding of this study and other studies, new screening strategies need to be developed that detect potential vision-threatening retinopathy early in clinical and nonclinical settings. Genetic risk factors for diabetes and DR should be identified, and the interactions between genes and metabolic control should be examined; these factors will help in risk stratification and in preventing vision loss (9). Therefore, implementing of novel, feasible, and sustainable strategies to control the growing current of DR is a significant challenge. Part of the challenge is the need for global level research strategic planning for preventing and treating DR.

Many clinical reviews and meta-analyses exist on DR, and scientometric studies investigating other topics in ophthalmology exist; however, quantitative description of publications specifically on DR is lacking. Recent bibliometric analysis of scientific publications has been performed for individual and institutional output analysis, and for assessing the scientific advancements and motivations of researchers and identifying current research directions in a specific field; fund assignments and subsequent research designs can be enhanced using such data because it will predict how this field will move forward (10, 11). Mapping the external and internal features of a scientific field by tracing the core production or citations, would aid in research that is more global strategic planning. Thus, we aimed to analyze the scientific productions on DR to define a general roadmap for future research strategic planning in this field.

## MATERIAL AND METHODS

### Data Source

A descriptive bibliometric study of scientific papers about DR was conducted. For this purpose, the ISI Web of Science database (available at <http://www.isiknowledge.com>) was used because it is a major source for bibliometrics, citations, and other academic impact information of scientific articles in various branches of sciences. All three resources available in the ISI web of science were used for this


purpose (Science Citation Index Expanded; Social Sciences Citation Index; the Arts & Humanities Citation Index, A&HCI).

### Search Strategies

For the best keywords, we created a list from the Medical Subject Headings (MeSH), which is provided by the National Library of Medicine (NLM, Bethesda, MD, USA) to index the contents of PubMed. The adopted search strategy was Title: ((Diabet\* and Retinopathy) or (Diabetic Retinopathy)) as the search keyword. This yielded 3228 publications. The '\*' is a wildcard that can take any value. Our search focused on articles published during 1993–2013. Our search was performed in Feb 2014. We included only research articles in the analysis and excluded meeting abstracts, case reports, review articles as well as letters.

### Data Analysis

We retrieved documents related to main journals in this field, articles' language, the publication year, first author, geographical distribution, institutional affiliations and citations of the paper by other papers from the ISI and analyzed with the analyze function provided by the ISI database. Also, we used the Journal Citation Reports (available at <http://scientific.thomson.com/products/jcr>) to derive journal's impact factor. Software for statistical analysis in this study was Microsoft Excel 2003 computer spreadsheet software (Microsoft; Redmond, WA, USA). Analysis of related articles by HistCite software was performed considering the topic's structure, history, and document relationships. We imported the bibliography derived from the web of science database to HistCite. Any articles that cited  $\geq 100$  were included in historiography of the DR research field from 1993 to 2013 (please refer to Appendix 1). Articles that were cited more than 100 times were evaluated by the country of affiliation of the first author and publishing journal. For identification of recent trends, the citation analysis was repeated for articles published from 2010 to 2013. For the citation analysis, two parameters were calculated: the local citation score (LCS) and the global citation score (GCS). The LCS lists all papers sorted by citation frequency within the local (i.e., the starting bibliography). By contrast, the GCS counts citations in the whole collection. For the citation burst analysis, the hundred keywords that generated the citation bursts were extracted, and then the nonspecific and general keywords were omitted.



**Figure 1. The Number of Papers Published Annually**  
The growth rate of 6.46% in the article numbers was observed.

**RESULTS**

**Annual Publication Number During 1993–2013**

There were 3,228 research articles on DR in the ISI Web of Science published during 1993–2013. These papers were drafted by 11,591 authors, 2,771 institutions, and 93 countries. The articles were published in 547 journals in 10 languages. Figure 1 demonstrates the growth rate (6.46% per year) of publications in this field.

**Citation Profile of Articles**

The total LCS citations were 12,830 times and the GCS citations were 62,327 times. The average citation per paper (C/P) was 19.31. Table 1 shows the articles that were cited ≥ 100. Appendix 1 shows the highly cited articles in this field. Figure 2 shows the histogram map of 20 years of research in this field. Keywords that generated citation bursts during this period were as follows: Metabolic control, Onset, Diabetes-mellitus, Glycosylated hemoglobin, Fluorescein angiography, Fluorophotometry, Neovascular glaucoma, Microangiopathy, Microalbuminuria, Glycation, Proliferative retinopathy, NIDDM, Proteinuria, Photocoagulation, Retinal blood-flow, VEGF, Maculopathy, Insulin, Nitric oxide, Screening, Telemedicine, Retinal microvascular abnormalities,

Oxidative stress, Bevacizumab, Vitrectomy, and inflammation (Fig. 3).

**Subject Analysis and Publisher of Documents**

The most frequent topics of the top 10 highly cited papers were translational research (30%) and epidemiologic studies (70%) (Table1).

**Profiles of Most Influential Authors and Journals**

The highest number of articles was published by Dr. R. Klein with 133 articles (Table 2). When analyzed by the number of papers in DR, 14 of the top 20 journals were ophthalmology journals and the remaining were diabetes journals. However, when using the same calculation based on the citation number (TLCS), 6 journals were diabetes journals, 12 journals were ophthalmology journals, and 2 journals were general subject medicine journals. When analyzed by the TGCS, highly cited papers were published in ophthalmology journals, diabetes journals, general medicine journals, neurology journals and pathology journals (Table 3). Most DR articles were in English (3,058 articles) followed by German (54 articles), French (47 articles), and Spanish (21 articles). Articles were written in a total of 10 languages (English,



German, French, Spanish, Portuguese, Russian, Chinese, Serbo-Croatian, Slovene, and Turkish).

### Geographical Distribution

Most of the top 10 Universities and institutions on the list are from the United States and Australia. The first two institutions are the University of Wisconsin and University of Melbourne, based on the number of

documents, and the University of Wisconsin and Harvard University in based on citations (Table 4).

In general, 93 countries promoted the field of DR by publishing articles. The United States, United Kingdom, and Japan had the highest number of documents, but the United States, United Kingdom, and Australia had the highest number of citations to their research papers in the field of DR (Table 5).

**Table 1. Articles With Highest Number of Citations (LCS)**

| # | Author/ Title / Journal  | CITATION |
|---|--|----------|
| 1 | Aiello Lp, Avery Rl, Arrigg Pg, Keyt Ba, Jampel Hd, Et Al.<br>Vascular Endothelial Growth-Factor In Ocular Fluid Of Patients With Diabetic-Retinopathy And Other Retinal Disorders<br>New England Journal Of Medicine. 1994 Dec 1; 331 (22): 1480-1487                             | 1,877    |
| 2 | Adamis Ap, Miller Jw, Bernal Mt, Damico Dj, Folkman J, Et Al.<br>Increased Vascular Endothelial Growth-Factor Levels In The Vitreous Of Eyes With Proliferative Diabetic-Retinopathy<br>American Journal Of Ophthalmology. 1994 Oct; 118 (4): 445-450                              | 745      |
| 3 | Shannon H, Duffy H, Dahms W, Mayer L, Brillion D, Et Al.<br>Retinopathy And Nephropathy In Patients With Type 1 Diabetes Four Years After A Trial Of Intensive Therapy.<br>New England Journal Of Medicine. 2000 Feb 10; 342 (6): 381-389  | 622      |
| 4 | Dyck Pj, Kratz Km, Karnes JI, Litchy Wj, Klein R, Et Al.<br>The Prevalence By Staged Severity Of Various Types Of Diabetic Neuropathy, Retinopathy, And Nephropathy In A Population-Based Cohort - The Rochester Diabetic Neuropathy Study<br>Neurology. 1993 Apr; 43 (4): 817-824 | 518      |
| 5 | Chaturvedi N, Sjolie Ak, Stephenson Jm, Abrahamian H, Keipes M, Et Al.<br>Effect Of Lisinopril On Progression Of Retinopathy In Normotensive People With Type 1 Diabetes<br>Lancet. 1998 Jan 3; 351 (9095): 28-31  | 393      |
| 6 | Wilkinson Cp, Ferris Fl, Klein Re, Lee Pp, Agardh Cd, Et Al.<br>Proposed International Clinical Diabetic Retinopathy And Diabetic Macular Edema Disease Severity Scales<br>Ophthalmology. 2003 Sep; 110 (9): 1677-1682   | 372      |
| 7 | Schrier Rw, Estacio Ro, Esler A, Mehler P<br>Effects Of Aggressive Blood Pressure Control In Normotensive Type 2 Diabetic Patients On Albuminuria, Retinopathy And Strokes<br>Kidney International. 2002 Mar; 61 (3): 1086-1097  | 367      |
| 8 | Jousen Am, Poulaki V, Le Ml, Koizumi K, Esser C, Et Al.<br>A Central Role For Inflammation In The Pathogenesis Of Diabetic Retinopathy<br>Faseb Journal. 2004 Jul; 18 (10): 1450-+   | 358      |
| 9 | Hammes Hp, Du Xl, Edelstein D, Taguchi T, Matsumura T, Et Al.<br>Benfotiamine Blocks Three Major Pathways Of Hyperglycemic Damage And Prevents Experimental Diabetic Retinopathy<br>Nature Medicine. 2003 Mar; 9 (3): 294-299  | 343      |



|    |   |     |
|----|---|-----|
| 10 | Miyamoto K, Khosrof S, Bursell Se, Rohan R, Murata T, Et Al.<br>Prevention Of Leukostasis And Vascular Leakage In Streptozotocin-Induced Diabetic Retinopathy Via Intercellular Adhesion Molecule-1 Inhibition<br>Proceedings Of The National Academy Of Sciences Of The United States Of America. 1999<br>Sep 14; 96 (19): 10836-10841 | 329 |
|----|---|-----|

## DISCUSSION

We analyzed the subject of highly cited papers, divided them into broad categories of clinical\translational versus basic science research (Appendix 1). Most highly cited papers are epidemiologic or translational science reports. Despite the enormous impact of DR on the quality of life and emotional status of patients, few articles among these highly cited papers addressed this subject. Highly cited reports were also addressing the following topics more frequently: laser photocoagulation and angiogenesis. As Appendix 2 shows, there is a recent trend toward more translational research such as biomarker discovery. Areas such as gene therapy and micro-RNA are among the recent hot topics. Citation burst analysis showed that certain topics are very popular such as the role of inflammation or oxidative

stress in the pathogenesis of DR. In general, in the field of ophthalmology, there was an increase in the proportion of articles related to medical retina, compared to other subspecialties, between 2005 and 2009. In an analytical study of the ophthalmology research papers, case-control or cohort studies comprised most study designs (40.1%), followed by nonanalytic studies (28.7%), basic science (24.6%), randomized controlled trials (RCTs) (3.3%), review articles (2.6%), and meta-analyses (0.3%) (12). However, this was not the trend in diabetes retinopathy research. The term "citation analysis" covers concepts such as journal impact factor (JIF), the immediacy index, and cited and citing half-lives. The results of citation analysis should be interpreted concurrently with the results of the JIF because ranking of research groups on the basis of JIF has little correlation to a ranking of the same groups on the basis of citation frequency.

**Table 2. The Most Active Authors in the Field of DR Research**

| #  | Author     | Recs | TLCS | TGCS |
|----|------------|------|------|------|
| 1  | Klein R    | 133  | 1653 | 6084 |
| 2  | Wong Ty    | 76   | 595  | 1868 |
| 3  | Klein Bek  | 69   | 861  | 2933 |
| 4  | Wang Jj    | 50   | 455  | 1504 |
| 5  | Moss Se    | 44   | 717  | 2642 |
| 6  | Sharma T   | 37   | 163  | 352  |
| 7  | Aiello Lp  | 35   | 506  | 3350 |
| 8  | Hammes Hp  | 35   | 164  | 1616 |
| 9  | Kowluru Ra | 34   | 276  | 1063 |
| 10 | Raman R    | 33   | 121  | 230  |

Thus, authors who are frequently cited but choose to publish in an appropriate but lower JIF-ranked journal would not receive the best evaluation from the institutional Journal Citation Report-based assessment of an author. Overall, in our study, there was no significant correlation between the JIFs and the citation frequency of articles. This can result from several factors; for example, journals with advance online publication had higher impact factors than journals without advance online publication. Thus, factors other than the quality of papers may affect the citation frequency of a paper (13). In a survey of 46 ophthalmology journals to identify the most frequently cited articles using the Science Citation Index Expanded (1975–2006), the 100 most cited articles were published in 13 journals, the utmost articles were in the Archives of Ophthalmology (n = 30), followed by Ophthalmology (n = 27). American Journal of Ophthalmology (n = 11) was in third place. The published

articles originated from 10 countries, led by the United States (n = 86) (14). Laser photocoagulation to treat DR was one of the major topics among the 100 most cited articles. In addition, we found that the h-index of DR was 98, which indicates the appreciation of the context of DR within vision research. Publications of Dr. Klein, who is the most active scientist in the field of DR research, are also among the top 100 most cited articles in the field of ophthalmology, which shows the importance of this field. Our results for the field of citation analysis showed that most citation clusters were generated by few countries and few journals, mostly from the United States and Australian institutions. This fact may be because of the overwhelming influence of the United States on research. However, it may also be because of a tendency for American authors to cite local papers and for authors in other parts of the world to publish in and cite American journals (15).




Fig.2. Histogram map of 20 years of research in DR

| Keywords                  | Strength | Begin | End  | 1992 - 2014 |
|---------------------------|----------|-------|------|-------------|
| Metabolic control         | 8.0699   | 1992  | 2001 |             |
| Onset                     | 7.8749   | 1992  | 2001 |             |
| Diabetes-mellitus         | 7.158    | 1992  | 1994 |             |
| Glycosylated hemoglobin   | 5.8617   | 1992  | 1997 |             |
| Fluorescein angiography   | 5.6114   | 1992  | 1998 |             |
| Fluorophotometry          | 5.0165   | 1992  | 1998 |             |
| Neovascular glaucoma      | 4.5041   | 1992  | 2000 |             |
| Microangiopathy           | 4.4163   | 1992  | 2000 |             |
| Microalbuminuria          | 13.4556  | 1994  | 2000 |             |
| Glycation                 | 3.4028   | 1994  | 1995 |             |
| Proliferative retinopathy | 5.2867   | 1995  | 2001 |             |
| NIDDM                     | 12.6527  | 1996  | 2001 |             |
| Proteinuria               | 5.6377   | 1996  | 2001 |             |
| Photocoagulation          | 3.8159   | 1996  | 1996 |             |



|                                     |         |      |      |  |
|-------------------------------------|---------|------|------|--|
| Retinal blood-flow                  | 3.4049  | 1996 | 1997 |  |
| VEGF                                | 4.3345  | 1997 | 2003 |  |
| Maculopathy                         | 3.5225  | 1997 | 2001 |  |
| Insulin                             | 6.8506  | 1998 | 2002 |  |
| Nitric oxide                        | 5.5548  | 2001 | 2003 |  |
| Screening                           | 6.3987  | 2002 | 2004 |  |
| Telemedicine                        | 4.4617  | 2002 | 2005 |  |
| Retinal microvascular abnormalities | 3.4268  | 2006 | 2007 |  |
| Oxidative stress                    | 10.1662 | 2009 | 2014 |  |
| Bevacizumab                         | 6.496   | 2009 | 2010 |  |
| Vitrectomy                          | 4.0998  | 2010 | 2010 |  |
| Inflammation                        | 11.8843 | 2011 | 2014 |  |

Figure 3. Keywords with the largest citation burst and the corresponding years

Table 3. Journals with Highest Number of Papers in This Field

| #  | Journal   | Records | Citation | 2 year IF | 5 year IF |
|----|---|---------|----------|-----------|-----------|
| 1  | Investigative Ophthalmology & Visual Science        | 167     | 4378     | 3.441     | 3.730     |
| 2  | Diabetes Care                                       | 162     | 4463     | 7.735     | 7.555     |
| 3  | Diabetic Medicine                                   | 124     | 2380     | 3.241     | 3.303     |
| 4  | British Journal Of Ophthalmology                    | 115     | 2845     | 2.725     | 3.023     |
| 5  | Ophthalmology                                       | 103     | 4349     | 5.563     | 5.777     |
| 6  | Retina-The Journal Of Retinal And Vitreous Diseases | 98      | 1482     | 2.825     | 2.761     |
| 7  | Diabetes Research And Clinical Practice             | 97      | 898      | 2.741     | 2.618     |
| 8  | American Journal Of Ophthalmology                   | 89      | 3275     | 3.631     | 4.292     |
| 9  | Diabetologia  | 87      | 2968     | 6.487     | 6.772     |
| 10 | Eye   | 83      | 1124     | 1.818     | 1.883     |





|    |   |    |      |       |       |
|----|---|----|------|-------|-------|
| 11 | Graefes Archive For Clinical And Experimental Ophthalmology | 82 | 1067 | 1.932 | 2.037 |
| 12 | Archives Of Ophthalmology                                   | 81 | 3787 | 3.826 | 4.160 |
| 13 | Diabetes  | 77 | 4552 | 7.895 | 8.611 |
| 14 | Journal Of Diabetes And Its Complications                   | 55 | 649  | 2.056 | 2.076 |
| 15 | Molecular Vision  | 52 | 499  | 1.987 | 2.311 |
| 16 | Ophthalmologica   | 48 | 427  | 1.412 | 1.236 |
| 17 | Acta Ophthalmologica Scandinavica                           | 47 | 456  | -     | -     |
| 18 | Clinical And Experimental Ophthalmology                     | 45 | 324  | 1.964 | 2.047 |
| 19 | Acta Ophthalmologica  | 43 | 379  | 2.345 | 2.428 |
| 20 | Current Eye Research  | 36 | 452  | 1.710 | 1.702 |

**Table 4. Institutions with highest number of papers**

| #  | Institution                      | Records | TLCS | TGCS |
|----|----------------------------------|---------|------|------|
| 1  | University Wisconsin             | 168     | 2020 | 7248 |
| 2  | University Melbourne             | 106     | 884  | 2721 |
| 3  | Harvard University               | 80      | 938  | 6029 |
| 4  | University Sydney                | 75      | 631  | 2205 |
| 5  | Natl University Singapore        | 64      | 501  | 1433 |
| 6  | Wayne State University           | 53      | 331  | 1584 |
| 7  | Johns Hopkins University         | 43      | 320  | 1160 |
| 8  | Northeastern Illinois University | 39      | 522  | 1921 |
| 9  | Case Western Reserve University  | 36      | 328  | 2064 |
| 10 | Aarhus University Hospital       | 31      | 240  | 976  |
| 11 | The University of Tokyo          | 31      | 63   | 312  |
| 12 | Singapore National Eye Center    | 30      | 149  | 345  |
| 13 | Joslin Diabetes Center           | 29      | 413  | 2911 |



|    |                               |    |     |      |
|----|-------------------------------|----|-----|------|
| 14 | Shanghai Jiao Tong University | 29 | 46  | 221  |
| 15 | Capital Med University        | 28 | 94  | 204  |
| 16 | University Heidelberg         | 28 | 112 | 1152 |
| 17 | Sankara Nethralaya            | 25 | 92  | 179  |
| 19 | University Oklahoma           | 25 | 130 | 654  |
| 20 | St Thomas Hospital            | 24 | 301 | 1102 |

**Table 5. Countries With Highest Number of Publications in the Field of DR**

| #  | Country         | Recs | TLCS | TGCS  |
|----|-----------------|------|------|-------|
| 1  | USA             | 837  | 5682 | 29687 |
| 2  | UK              | 348  | 1948 | 7952  |
| 3  | Japan           | 330  | 1051 | 6373  |
| 4  | Peoples R China | 220  | 386  | 1557  |
| 5  | Australia       | 206  | 1210 | 4050  |
| 6  | Germany         | 184  | 736  | 4974  |
| 7  | Italy           | 123  | 348  | 1629  |
| 8  | India           | 115  | 477  | 1319  |
| 9  | Spain           | 100  | 219  | 1218  |
| 10 | Denmark         | 92   | 515  | 2226  |
| 11 | France          | 90   | 298  | 1476  |
| 12 | Singapore       | 83   | 551  | 1584  |
| 13 | Brazil          | 76   | 204  | 837   |
| 14 | Sweden          | 75   | 318  | 1591  |
| 15 | Turkey          | 68   | 132  | 634   |
| 16 | Canada          | 66   | 221  | 1163  |
| 17 | South Korea     | 66   | 118  | 517   |

Factors that influence the number of citations that can be obtained by a scientific paper include (1) the merit of journal of publication and (2) the number of references that citing papers use, which is substantially affected by the differences between fields. Also, (3) the number of scientists active in the same field or subfield is important when there are relatively few colleagues working on the same topic. Thus, if for example, more scientists are working on the laser treatment of DR, then there would be heterogeneity between subfields. This may account for the difference in the number of citations between the various types of research papers in DR. For example, scientists active in more basic fields can obtain different numbers of citations than more clinically oriented scientists (15). Among the top 100 cited articles, we could determine that scientists active in the field of translational research and those who were authors on epidemiological studies and RCTs could receive significantly more citations. Much of the burden of visual disorders could be alleviated through at least the three routes: prevention and diagnostic screening, medical treatment of diagnosed conditions, and rehabilitation and support services for those with visual impairment.

Each year, tens of thousands of articles in these areas are published that discuss the medical, policy, and economic aspects of visual problems. Despite this excellent and growing body of work, several areas of research remain virtually nonexistent such as comparing the population benefits of investments in medical treatments for people with vision-threatening disease, compared to rehabilitation and adaptive services for people who have previously acquired impairment. To provide better guidelines for vision research, five major priorities for research were determined by four authorities in A Vision



for Horizon 2020. These priorities included neuron–glia interaction, gene therapy in retinal diseases, micro-incision cataract surgery, and femtosecond laser surgery. Improving care and care delivery in the Third World countries has also been mentioned as a research priority. The experts felt that these priority settings may be biased since they are significantly different from topics set by other authorities (16). The results of our and similar studies would help to more accurately determine research priorities in the field of DR. In conclusion, this report is the first scientometric analysis of the field of DR and can be a roadmap for future research policy in this important field.

In conclusion, this report as the first scientometric analysis of the field of DR, can be regarded as roadmap for future research policy making in this important field.

#### DISCLOSURE

The authors have no financial or propriety interest in any material or method mentioned in this article.

#### REFERENCES

1. Data from the International Federation of Diabetes. Available at: <http://www.idf.org/diabetesatlasDiabetic>
2. Yau JW, Rogers SL, Kawasaki R, Lamoureux EL, Kowalski JW, Bek T, Chen SJ, Dekker JM, Fletcher A, Grauslund J, Haffner S, Hamman RF, Ikram MK, Kayama T, Klein BE, Klein R, Krishnaiah S, Mayurasakorn K, O'Hare JP, Orchard TJ, Porta M, Rema M, Roy MS, Sharma T, Shaw J, Taylor H, Tielsch JM, Varma R, Wang JJ, Wang N, West S, Xu L, Yasuda M, Zhang X, Mitchell P, Wong TY; Meta-Analysis for Eye Disease (META-EYE) Study Group. Global prevalence and major risk factors of diabetic retinopathy. *Diabetes Care*. 2012 Mar;35(3):556-64. Epub 2012 Feb 1. doi: 10.2337/dc11-1909. PMID:22301125
3. Threatt J, Williamson JF, Huynh K, Davis RM. Ocular disease, knowledge and technology applications in patients with diabetes. *Am J Med Sci*. 2013 Apr; 345(4):266-70. doi: 10.1097/MAJ.0b013e31828aa6fb. PMID: 23531956
4. Ruta LM, Magliano DJ, Lemesurier R, Taylor HR, Zimmet PZ, Shaw JE. Prevalence of diabetic retinopathy in Type 2 diabetes in developing and developed countries. *Diabet Med*. 2013 Apr;30(4):387-98. doi: 10.1111/dme.12119. PMID: 23331210
5. Zheng Y, He M, Congdon N. The worldwide epidemic of diabetic retinopathy. *Indian J Ophthalmol*. 2012 Sep-Oct;60(5):428-31. doi: 10.4103/0301-4738.100542. PMID: 22944754
6. Ding J, Wong TY. Current epidemiology of diabetic retinopathy and diabetic macular edema. *Curr Diab Rep*. 2012 Aug;12(4):346-54. doi: 10.1007/s11892-012-0283-6. PMID: 22585044
7. Zambelli-Weiner A, Crews JE, Friedman DS. Disparities in adult vision health in the United States. *Am J Ophthalmol*. 2012 Dec;154(6 Suppl):S23-30.e1. PMID: 22633355
8. Wong TY, Hyman L. Population-based studies in ophthalmology. *Am J Ophthalmol*. 2008 Nov;146(5):656-63. PMID: 18984085
9. Gardner TW, Abcouwer SF, Barber AJ, Jackson GR. An integrated approach to diabetic retinopathy research. *Arch Ophthalmol*. 2011 Feb;129(2):230-5. PMID: 21320973
10. Garfield E. Citation analysis as a tool in journal evaluation. *Science*. 1972 Nov 3;178(4060):471-9. PMID: 5079701
11. Moghimi M, Fathi M, Marashi A, Kamani F, Habibi G, Hirbod-Mobarakeh A, Ghaemi M, Hosseini-Sarajehlou M. A scientometric analysis of 20 years of research on breast reconstruction surgery: a guide for research design and journal selection. *Arch Plast Surg*. 2013 Mar;40(2):109-15. doi: 10.5999/aps.2013.40.2.109. PMID: 23605554
12. Kumar A, Cheeseman R, Durnian JM. Subspecialization of the ophthalmic literature: a review of the publishing trends of the top general, clinical ophthalmic journals. *Ophthalmology*. 2011 Jun;118(6):1211-4. doi: 10.1016/j.ophtha.2010.10.023. Epub 2011 Jan 26.
13. Sims JL, McGhee CN. Citation analysis and journal impact factors in ophthalmology and vision science journals. *Clin Experiment Ophthalmol*. 2003 Feb; 31(1):14-22. PMID: 12580889
14. Ohba N, Nakao K, Isashiki Y, Ohba A. The 100 most frequently cited articles in ophthalmology journals. *Arch Ophthalmol*. 2007 Jul; 125(7):952-60. PMID: 17620577
15. Ophthof T. Differences in citation frequency of clinical and basic science papers in cardiovascular research. *Med Biol Eng Comput*. 2011 Jun;49(6):613-21. doi: 10.1007/s11517-011-0783-6. PMID: 21567267
16. Spaeth GL. Priorities of ophthalmic research. *Ophthalmic Res*. 2013;49(3):122-6.



## Appendix-1: Top most cited articles in the past 20 years.

| #  | Author / Title/ Journal   | Citation |
|----|---|----------|
| 1  | 169 Aiello LP, Avery RL, Arrigg PG, Keyt BA, Jampel HD, et al.<br>Vascular Endothelial Growth-Factor In Ocular Fluid Of Patients With Diabetic-Retinopathy And Other Retinal Disorders<br>New England Journal Of Medicine. 1994 Dec 1; 331 (22): 1480-1487  | 1877     |
| 2  | 150 Adamis AP, Miller JW, Bernal MT, Damico DJ, Folkman J, et al.<br>Increased Vascular Endothelial Growth-Factor Levels In The Vitreous Of Eyes With Proliferative Diabetic-Retinopathy<br>American Journal Of Ophthalmology. 1994 OCT; 118 (4): 445-450   | 745      |
| 3  | 693 Shannon H, Duffy H, Dahms W, Mayer L, Brillion D, et al.<br>Retinopathy and nephropathy in patients with type 1 diabetes four years after a trial of intensive therapy.<br>NEW ENGLAND JOURNAL OF MEDICINE. 2000 FEB 10; 342 (6): 381-389   | 622      |
| 4  | 43 Dyck PJ, Kratz KM, Karnes JL, Litchy WJ, Klein R, et al.<br>The Prevalence By Staged Severity Of Various Types Of Diabetic Neuropathy, Retinopathy, And Nephropathy In A Population-Based Cohort - The Rochester Diabetic Neuropathy Study<br>NEUROLOGY. 1993 APR; 43 (4): 817-824   | 518      |
| 5  | 472 Chaturvedi N, Sjolie AK, Stephenson JM, Abrahamian H, Keipes M, et al.<br>Effect of lisinopril on progression of retinopathy in normotensive people with type 1 diabetes<br>LANCET. 1998 JAN 3; 351 (9095): 28-31   | 393      |
| 6  | 1114 Wilkinson CP, Ferris FL, Klein RE, Lee PP, Agardh CD, et al.<br>Proposed international clinical diabetic retinopathy and diabetic macular edema disease severity scales<br>Ophthalmology. 2003 SEP; 110 (9): 1677-1682   | 372      |
| 7  | 917 Schrier RW, Estacio RO, Esler A, Mehler P<br>Effects of aggressive blood pressure control in normotensive type 2 diabetic patients on albuminuria, retinopathy and strokes<br>KIDNEY INTERNATIONAL. 2002 MAR; 61 (3): 1086-1097   | 367      |
| 8  | 1216 Jousseaume AM, Poulaki V, Le ML, Koizumi K, Esser C, et al.<br>A central role for inflammation in the pathogenesis of diabetic retinopathy<br>FASEB JOURNAL. 2004 JUL; 18 (10): 1450-+   | 358      |
| 9  | 1043 Hammes HP, Du XL, Edelstein D, Taguchi T, Matsumura T, et al.<br>Benfotiamine blocks three major pathways of hyperglycemic damage and prevents experimental diabetic retinopathy<br>Nature Medicine. 2003 MAR; 9 (3): 294-299  | 343      |
| 10 | 650 Miyamoto K, Khosrof S, Bursell SE, Rohan R, Murata T, et al.<br>Prevention of leukostasis and vascular leakage in streptozotocin-induced diabetic retinopathy via intercellular adhesion molecule-1 inhibition<br>Proceedings Of The National Academy Of Sciences Of The United States Of America. 1999 SEP 14; 96 (19): 10836-10841                    | 329      |
| 11 | 306 Mizutani M, Kern TS, Lorenzi M<br>Accelerated death of retinal microvascular cells in human and experimental diabetic retinopathy<br>Journal Of Clinical Investigation. 1996 JUN 15; 97 (12): 2883-2890   | 322      |
| 12 | 1187 Kempner JH, O'Colman BJ, Leske C, Haffner SM, Klein R, et al.<br>The prevalence of diabetic retinopathy among adults in the United States<br>ARCHIVES OF OPHTHALMOLOGY. 2004 APR; 122 (4): 552-563   | 322      |
| 13 | 639 Antonetti DA, Barber AJ, Hollinger LA, Wolpert EB, Gardner TW<br>Vascular endothelial growth factor induces rapid phosphorylation of tight junction proteins occludin and zonula occluden 1 - A potential mechanism for vascular permeability in diabetic retinopathy and tumors<br>JOURNAL OF BIOLOGICAL CHEMISTRY. 1999 AUG 13; 274 (33): 23463-23467 | 290      |
| 14 | 1530 Avery RL, Pearlman J, Pieramici DJ, Rabena MD, Castellarin AA, et al.  | 288      |



|    |  |     |
|----|--|-----|
|    | Intravitreal bevacizumab (Avastin) in the treatment of proliferative diabetic retinopathy<br>OPHTHALMOLOGY. 2006 OCT; 113 (10): 1695-1705  |     |
| 15 | 934 Awata T, Inoue K, Kurihara S, Ohkubo T, Watanabe M, et al.<br>A common polymorphism in the 5'-untranslated region of the VEGF gene is associated with diabetic retinopathy in type 2 diabetes<br>DIABETES. 2002 MAY; 51 (5): 1635-1639   | 286 |
| 16 | 557 Klein R, Klein BEK, Moss SE, Cruickshanks KJ<br>The Wisconsin epidemiologic study of diabetic retinopathy: XVII - The 14-year incidence and progression of diabetic retinopathy and associated risk factors in type 1 diabetes<br>OPHTHALMOLOGY. 1998 OCT; 105 (10): 1801-1815                 | 279 |
| 17 | 800 Stratton IM, Kohner EM, Aldington SJ, Turner RC, Holman RR, et al.<br>UKPDS 50: Risk factors for incidence and progression of retinopathy in Type II diabetes over 6 years from diagnosis<br>DIABETOLOGIA. 2001 FEB; 44 (2): 156-163   | 273 |
| 18 | 897 Jousseaume AM, Poulaki V, Mitsiades N, Kirchhof B, Koizumi K, et al.<br>Nonsteroidal anti-inflammatory drugs prevent early diabetic retinopathy via TNF-alpha suppression<br>FASEB JOURNAL. 2002 JAN; 16 (1): 438-+  | 257 |
| 19 | 158 Malecaze F, Clamens S, Simorrepatel V, Mathis A, Chollet P, et al.<br>Detection Of Vascular Endothelial Growth-Factor Messenger-Rna And Vascular Endothelial Growth Factor-Like Activity In Proliferative Diabetic-Retinopathy<br>ARCHIVES OF OPHTHALMOLOGY. 1994 NOV; 112 (11): 1476-1482     | 247 |
| 20 | 138 Klein R, Klein Bek, Moss Se, Cruickshanks KJ<br>The Wisconsin Epidemiologic-Study of Diabetic-Retinopathy .14. 10-Year Incidence and Progression of Diabetic-Retinopathy<br>ARCHIVES OF OPHTHALMOLOGY. 1994 SEP; 112 (9): 1217-1228  | 244 |
| 21 | 1457 Spaide RF, Fisher YL<br>Intravitreal bevacizumab (Avastin) treatment of proliferative diabetic retinopathy complicated by vitreous hemorrhage<br>Retina-The journal Of Retinal And Vitreous Diseases. 2006 Mar; 26 (3): 275-278   | 242 |
| 22 | 1711 Keech AC, Mitchell P, Summonen PA, O'Day J, Davis TME, et al.<br>Effect of fenofibrate on the Need for Laser Treatment for Diabetic Retinopathy (FIELD study): a Randomized Controlled Trial<br>LANCET. 2007 NOV 17; 370 (9600): 1687-1697  | 229 |
| 23 | 356 Amin RH, Frank RN, Kennedy A, Elliott D, Puklin JE, et al.<br>Vascular endothelial growth factor is present in glial cells of the retina and optic nerve of human subjects with nonproliferative diabetic retinopathy<br>investigative Ophthalmology & Visual Science. 1997 Jan; 38 (1): 36-47 | 222 |
| 24 | 319 Chew EY, Klein ML, Ferris FL, Remaley NA, Murphy RP, et al.<br>Association of elevated serum lipid levels with retinal hard exudate in diabetic retinopathy - Early treatment diabetic retinopathy study (ETDRS) report 22<br>Archives Of Ophthalmology. 1996 SEP; 114 (9): 1079-1084          | 220 |
| 25 | 1388 Watanabe D, Suzuma K, Matsui S, Kurimoto M, Kiryu J, et al.<br>Erythropoietin as a retinal angiogenic factor in proliferative diabetic retinopathy<br>New England Journal Of Medicine. 2005 AUG 25; 353 (8): 782-792  | 220 |
| 26 | 197 Aldington SJ, Kohner Em, Meuer S, Klein R, Sjolie Ak<br>Methodology For Retinal Photography And Assessment Of Diabetic-Retinopathy - The Eurodiab Iddm Complications Study<br>Diabetologia. 1995 Apr; 38 (4): 437-444  | 219 |
| 27 | 511 Lieth E, Barber AJ, Xu BY, Dice C, Ratz MJ, et al.<br>Glial reactivity and impaired glutamate metabolism in short-term experimental diabetic retinopathy<br>DIABETES. 1998 May; 47 (5): 815-820  | 219 |
| 28 | 187 Klein R, Klein Bek, Moss Se, Cruickshanks KJ<br>The Wisconsin Epidemiologic-Study of Diabetic-Retinopathy .15. The Long-Term Incidence of Macular Edema<br>OPHTHALMOLOGY. 1995 JAN; 102 (1): 7-16  | 211 |
| 29 | 2283 Cheung N, Mitchell P, Wong TY   | 199 |



|    |   |     |
|----|---|-----|
|    | Diabetic retinopathy<br>LANCET. 2010 JUL 10; 376 (9735): 124-136  |     |
| 30 | 970 Stitt A, Gardiner TA, Anderson NL, Canning P, Frizzell N, et al.<br>The AGE inhibitor pyridoxamine inhibits development of retinopathy in experimental diabetes<br>DIABETES. 2002 SEP; 51 (9): 2826-2832  | 196 |
| 31 | 852 Kowluru RA, Tang J, Kern TS<br>Abnormalities of retinal metabolism in diabetes and experimental galactosemia VII. Effect of long-term administration of antioxidants on the development of retinopathy<br>Diabetes. 2001 AUG; 50 (8): 1938-1942   | 193 |
| 32 | 1081 Kramer HJ, Nguyen QD, Curhan G, Hsu CY<br>Renal insufficiency in the absence of albuminuria and retinopathy among adults with type 2 diabetes mellitus<br>Jama-Journal Of The American Medical Association. 2003 JUN 25; 289 (24): 3273-3277   | 193 |
| 33 | 2285 Chew EY, Ambrosius WT, Davis MD, Danis RP, Gangaputra S, et al.<br>Effects of Medical Therapies on Retinopathy Progression in Type 2 Diabetes.<br>New England Journal Of Medicine. 2010 JUL 15; 363 (3): 233-244   | 186 |
| 34 | 486 Mizutani M, Gerhardinger C, Lorenzi M<br>Muller cell changes in human diabetic retinopathy<br>DIABETES. 1998 MAR; 47 (3): 445-449   | 185 |
| 35 | 205 Tarnow L, Cambien F, Rossing P, Nielsen Fs, Hansen Bv, et al.<br>Lack Of Relationship Between An Insertion Deletion Polymorphism In The Angiotensin I-Converting Enzyme Gene And Diabetic Nephropathy And Proliferative Retinopathy In Iddm Patients<br>DIABETES. 1995 MAY; 44 (5): 489-494       | 181 |
| 36 | 463 Fujisawa T, Ikegami H, Kawaguchi Y, Hamada Y, Ueda H, et al.<br>Meta-analysis of association of insertion/deletion polymorphism of angiotensin I-converting enzyme gene with diabetic nephropathy and retinopathy<br>DIABETOLOGIA. 1998 JAN; 41 (1): 47-53  | 179 |
| 37 | 724 Rungger-Brandle E, Dosso AA, Leuenberger PM<br>Glial reactivity, an early feature of diabetic retinopathy<br>Investigative Ophthalmology & Visual Science. 2000 JUN; 41 (7): 1971-1980  | 179 |
| 38 | 178 Shamooh H, Duffy H, Fleischer N, Engel S, Saenger P, et al.<br>The Effect Of Intensive Diabetes Treatment On The Progression Of Diabetic-Retinopathy In Insulin-Dependent Diabetes-Mellitus - The Diabetes Control And Complications Trial<br>Archives Of Ophthalmology. 1995 Jan; 113 (1): 36-51 | 176 |
| 39 | 216 Kohner Em, Patel V, Rassam Smb<br>Role Of Blood-Flow And Impaired Autoregulation In The Pathogenesis Of Diabetic-Retinopathy<br>DIABETES. 1995 Jun; 44 (6): 603-607   | 174 |
| 40 | 484 Kohner EM, Aldington SJ, Stratton IM, Manley SE, Holman RR, et al.<br>United kingdom prospective diabetes study, 30 - Diabetic retinopathy at diagnosis of non-insulin-dependent diabetes mellitus associated risk factors<br>Archives Of Ophthalmology. 1998 MAR; 116 (3): 297-303               | 174 |
| 41 | 981 Hammes HP, Lin JH, Renner O, Shani M, Lundqvist A, et al.<br>Pericytes and the pathogenesis of diabetic retinopathy<br>DIABETES. 2002 OCT; 51 (10): 3107-3112   | 174 |
| 42 | 537 Harris MI, Klein R, Cowie CC, Rowland M, Byrd-Holt DD<br>Is the risk of diabetic retinopathy greater in non-Hispanic blacks and Mexican Americans than in non-Hispanic whites with type 2 diabetes? A US population study<br>DIABETES CARE. 1998 AUG; 21 (8): 1230-1235                           | 170 |
| 43 | 264 Javitt JC, Aiello LP<br>Cost-effectiveness of detecting and treating diabetic retinopathy<br>ANNALS OF INTERNAL MEDICINE. 1996 JAN 1; 124 (1): 164-169  | 167 |



|    |  |     |
|----|--|-----|
| 44 | 1449 Wong TY, Klein R, Islam A, Frances M, Folsom AR, et al.<br>Diabetic retinopathy in a multi-ethnic cohort in the United States<br>American Journal Of Ophthalmology. 2006 MAR; 141 (3): 446-455  | 165 |
| 45 | 313 Tachi N, Ogino N<br>Vitrectomy for diffuse macular edema in cases of diabetic retinopathy<br>American Journal Of Ophthalmology. 1996 AUG; 122 (2): 258-260   | 162 |
| 46 | 413 Ambati J, Chalam KV, Chawla DK, D'Angio CT, Guillet EG, et al.<br>Elevated gamma-aminobutyric acid, glutamate, and vascular endothelial growth factor levels in the vitreous of patients with proliferative diabetic retinopathy<br>Archives Of Ophthalmology. 1997 SEP; 115 (9): 1161-1166  | 162 |
| 47 | 290 Bursell SE, Clermont AC, Kinsley BT, Simonson DC, Aiello LM, et al.<br>Retinal blood flow changes in patients with insulin-dependent diabetes mellitus and no diabetic retinopathy - A video fluorescein angiography study<br>Investigative Ophthalmology & Visual Science. 1996 APR; 37 (5): 886-897  | 160 |
| 48 | 485 Hammes HP, Lin JH, Bretzel RG, Brownlee M, Breier G<br>Upregulation of the vascular endothelial growth factor vascular endothelial growth factor receptor system in experimental background diabetic retinopathy of the rat<br>DIABETES. 1998 MAR; 47 (3): 401-406   | 159 |
| 49 | 769 Kern TS, Tang J, Mizutani M, Kowluru RA, Nagaraj RH, et al.<br>Response of capillary cell death to aminoguanidine predicts the development of retinopathy: Comparison of diabetes and galactosemia<br>Investigative Ophthalmology & Visual Science. 2000 NOV; 41 (12): 3972-3978   | 158 |
| 50 | 1340 Krady JK, Basu A, Allen CM, Xu YP, LaNoue KF, et al.<br>Minocycline reduces proinflammatory cytokine expression, microglial activation, and caspase-3 activation in a rodent model of diabetic retinopathy<br>DIABETES. 2005 MAY; 54 (5): 1559-1565   | 158 |
| 51 | 1405 Genuth S, Sun WJ, Cleary P, Sell DR, Dahms W, et al.<br>Glycation and carboxymethyllysine levels in skin collagen predict the risk of future 10-year progression of diabetic retinopathy and nephropathy in the diabetes control and complications trial and epidemiology of diabetes interventions and complications participants with type 1 diabetes<br>DIABETES. 2005 NOV; 54 (11): 3103-3111 | 152 |
| 52 | 843 Kern TS, Engerman RL<br>Pharmacological inhibition of diabetic retinopathy - Aminoguanidine and aspirin<br>DIABETES. 2001 JUL; 50 (7): 1636-1642   | 151 |
| 53 | 814 Jonas JB, Hayler JK, Sofker A, Panda-Jonas S<br>Intravitreal injection of crystalline cortisone as adjunctive treatment of proliferative diabetic retinopathy<br>American Journal Of Ophthalmology. 2001 APR; 131 (4): 468-471   | 144 |
| 54 | 1905 Chaturvedi N, Porta M, Klein R, Orchard T, Fuller J, et al.<br>Effect of candesartan on prevention (DIRECT-Prevent 1) and progression (DIRECT-Protect 1) of retinopathy in type 1 diabetes: randomised, placebo-controlled trials<br>LANCET. 2008 OCT 18; 372 (9647): 1394-1402   | 142 |
| 55 | 1904 Sjolie AK, Klein R, Porta M, Orchard T, Fuller J, et al.<br>Effect of candesartan on progression and regression of retinopathy in type 2 diabetes (DIRECT-Protect 2): a randomised placebo-controlled trial<br>LANCET. 2008 OCT 18; 372 (9647): 1385-1393   | 141 |
| 56 | 480 Davis MD, Fisher MR, Gangnon RE, Barton F, Aiello LM, et al.<br>Risk factors for high-risk proliferative diabetic retinopathy and severe visual loss: Early treatment diabetic retinopathy study report #18<br>Investigative Ophthalmology & Visual Science. 1998 Feb; 39 (2): 233-252   | 140 |
| 57 | 1023 Beck RW, Moke PS, Turpin AH, Ferris FL, Sangiovanni JP, et al.<br>A computerized method of visual acuity testing: Adaptation of the early treatment of diabetic retinopathy study testing protocol  | 139 |



|    |   |     |
|----|---|-----|
|    | American Journal Of Ophthalmology. 2003 FEB; 135 (2): 194-205   |     |
| 58 | 964 Enge M, Bjarnegard M, Gerhardt H, Gustafsson E, Kalen M, et al.<br>Endothelium-specific platelet-derived growth factor-B ablation mimics diabetic retinopathy<br>Embo Journal. 2002 AUG 15; 21 (16): 4307-4316  | 138 |
| 59 | 985 Walter T, Klein JC, Massin P, Erginay A<br>A contribution of image processing to the diagnosis of diabetic retinopathy - Detection of exudates in color fundus images of the human retina<br>ieee transactions on medical imaging. 2002 Oct; 21 (10): 1236-1243   | 136 |
| 60 | 437 Palmowski AM, Sutter EE, Bearse MA, Fung W<br>Mapping of retinal function in diabetic retinopathy using the multifocal electroretinogram<br>Investigative Ophthalmology & Visual Science. 1997 NOV; 38 (12): 2586-2596  | 134 |
| 61 | 1255 Matthews DR, Stratton IM, Aldington SJ, Holman RR, Kohner EM<br>Risks of progression of retinopathy and vision loss related to tight blood pressure control in type 2 diabetes mellitus - UKPDS 69<br>Archives Of Ophthalmology. 2004 NOV; 122 (11): 1631-1640   | 131 |
| 62 | 1257 Zheng L, Szabo C, Kern TS<br>Poly(ADP-ribose) polymerase is involved in the development of diabetic retinopathy via regulation of nuclear factor-kappa B<br>DIABETES. 2004 NOV; 53 (11): 2960-2967   | 131 |
| 63 | 836 Hudson BI, Stickland MH, Futers TS, Grant PJ<br>Effects of novel polymorphisms in the RAGE gene on transcriptional regulation and their association with diabetic retinopathy<br>DIABETES. 2001 JUN; 50 (6): 1505-1511  | 128 |
| 64 | 966 Ogata N, Nishikawa M, Nishimura T, Mitsuma Y, Matsumura M<br>Unbalanced vitreous levels of pigment epithelium-derived factor and vascular endothelial growth factor in diabetic retinopathy<br>American Journal Of Ophthalmology. 2002 SEP; 134 (3): 348-353  | 125 |
| 65 | 1367 Aiello LP<br>The effect of ruboxistaurin on visual loss in patients with moderately severe to very severe nonproliferative diabetic retinopathy initial - Results of the protein kinase C beta inhibitor diabetic retinopathy study (PKC-DRS) multicenter randomized clinical trial<br>DIABETES. 2005 JUL; 54 (7): 2188-2197 | 125 |
| 66 | 240 ELNER SG, ELNER VM, JAFFE GJ, STUART A, KUNKEL SL, et al.<br>Cytokines In Proliferative Diabetic-Retinopathy And Proliferative Vitreoretinopathy<br>Current Eye Research. 1995 NOV; 14 (11): 1045-1053  | 123 |
| 67 | 363 Sjolie AK, Stephenson J, Aldington S, Kohner E, Janka H, et al.<br>Retinopathy and vision loss in insulin dependent diabetes in Europe - The EURODIAB IDDM complications study<br>OPHTHALMOLOGY. 1997 FEB; 104 (2): 252-260   | 120 |
| 68 | 1188 Hammes HP, Lin JH, Wagner P, Feng Y, vom Hagen F, et al.<br>Angiopoietin-2 causes pericyte dropout in the normal retina - Evidence for involvement in diabetic retinopathy<br>DIABETES. 2004 APR; 53 (4): 1104-1110  | 120 |
| 69 | 1273 Kowluru RA, Odenbach S<br>Effect of long-term administration of alpha-lipoic acid on retinal capillary cell death and the development of retinopathy in diabetic rats<br>DIABETES. 2004 DEC; 53 (12): 3233-3238  | 119 |
| 70 | 206 Chew Ey, Mills JL, Metzger Be, Remaley Na, Jovanovicpeterson L, et al.<br>Metabolic Control And Progression Of Retinopathy - The Diabetes In Early-Pregnancy Study<br>Diabetes Care. 1995 May; 18 (5): 631-637  | 116 |
| 71 | 931 Jousen AM, Poulaki V, Tsujikawa A, Qin WY, Qaum T, et al.<br>Suppression of diabetic retinopathy with angiopoietin-1<br>American Journal Of Pathology. 2002 MAY; 160 (5): 1683-1693   | 115 |
| 72 | 694 Vijan S, Hofer TP, Hayward RA<br>Cost-utility analysis of screening intervals for diabetic retinopathy in patients with type 2 diabetes mellitus<br>JAMA-journal of the American Medical Association. 2000 FEB 16; 283 (7): 889-896   | 114 |





|    |  |     |
|----|--|-----|
| 73 | 813 Bursell SE, Cavallerano JD, Cavallerano AA, Clermont AC, Birkmire-Peters D, et al.<br>Stereo nonmydriatic digital-video color retinal imaging compared with early treatment diabetic retinopathy study seven standard field 35-mm stereo color photos for determining level of diabetic retinopathy<br>OPHTHALMOLOGY. 2001 MAR; 108 (3): 572-585 | 114 |
| 74 | 1003 Goebel W, Kretzchmar-Gross T<br>Retinal thickness in diabetic retinopathy - A study using optical coherence tomography (OCT)<br>RETINA-THE JOURNAL OF RETINAL AND VITREOUS DISEASES. 2002 DEC; 22 (6): 759-767  | 114 |
| 75 | 1557 Abraham P, Adelman RA, Alfaro DV, Anand R, Antoszyk A, et al.<br>Effect of ruboxistaurin on visual loss in patients with diabetic retinopathy<br>OPHTHALMOLOGY. 2006 DEC; 113 (12): 2221-2230   | 114 |
| 76 | 1541 Jorge R, Costa RA, Comt DC, Cintra LP, Scott IU<br>Intravitreal bevacizumab (Avastin) for persistent new vessels in diabetic retinopathy (IBEPE Study)<br>RETINA-THE JOURNAL OF RETINAL AND VITREOUS DISEASES. 2006 NOV-DEC; 26 (9): 1006-1013  | 112 |
| 77 | 219 KO BCB, LAM KSL, WAT NMS, CHUNG SSM<br>An (A-C)(N) Dinucleotide Repeat Polymorphic Marker At The 5'-End Of The Aldose Reductase Gene Is Associated With Early-Onset Diabetic-Retinopathy In Niddm Patients<br>DIABETES. 1995 JUL; 44 (7): 727-732  | 111 |
| 78 | 1179 Lyons TJ, Jenkins AJ, Zheng DY, Lackland DT, McGee D, et al.<br>Diabetic retinopathy and serum lipoprotein subclasses in the DCCT/EDIC cohort<br>INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE. 2004 MAR; 45 (3): 910-918  | 109 |
| 79 | 273 Peer J, Folberg R, Itin A, Gnessin H, Hemo I, et al.<br>Upregulated expression of vascular endothelial growth factor in proliferative diabetic retinopathy<br>BRITISH JOURNAL OF OPHTHALMOLOGY. 1996 MAR; 80 (3): 241-245  | 108 |
| 80 | 1759 Arevalo JF, Maia M, Flynn HW, Saravia M, Avery RL, et al.<br>Tractional retinal detachment following intravitreal bevacizumab (Avastin) in patients with severe proliferative diabetic retinopathy<br>BRITISH JOURNAL OF OPHTHALMOLOGY. 2008 FEB; 92 (2): 213-216   | 108 |
| 81 | 268 Limb GA, Chignell AH, Green W, LeRoy F, Dumonde DC<br>Distribution of TNF alpha and its reactive vascular adhesion molecules in fibrovascular membranes of proliferative diabetic retinopathy<br>BRITISH JOURNAL OF OPHTHALMOLOGY. 1996 FEB; 80 (2): 168-173   | 106 |
| 82 | 510 Boulton M, Foreman D, Williams G, McLeod D<br>VEGF localisation in diabetic retinopathy<br>BRITISH JOURNAL OF OPHTHALMOLOGY. 1998 MAY; 82 (5): 561-568   | 106 |
| 83 | 2300 Zhang XZ, Saaddine JB, Chou CF, Cotch MF, Cheng YJ, et al.<br>Prevalence of Diabetic Retinopathy in the United States, 2005-2008<br>JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION. 2010 AUG 11; 304 (6): 649-656   | 106 |
| 84 | 1347 Giebel SJ, Menicucci G, McGuire PG, Das A<br>Matrix metalloproteinases in early diabetic retinopathy and their role in alteration of the blood-retinal barrier<br>LABORATORY INVESTIGATION. 2005 MAY; 85 (5): 597-607   | 104 |
| 85 | 901 Sinthanayothin C, Boyce JF, Williamson TH, Cook HL, Mensah E, et al.<br>Automated detection of diabetic retinopathy on digital fundus images<br>DIABETIC MEDICINE. 2002 FEB; 19 (2): 105-112   | 102 |
| 86 | 1176 Ray D, Mishra M, Ralph S, Read I, Davies R, et al.<br>Association of the VEGF gene with proliferative diabetic retinopathy but not proteinuria in diabetes<br>DIABETES. 2004 MAR; 53 (3): 861-864   | 102 |
| 87 | 1482 Oshima Y, Sakaguchi H, Gomi F, Tano Y<br>Regression of iris neovascularization after intravitreal injection of bevacizumab in patients with proliferative diabetic retinopathy<br>AMERICAN JOURNAL OF OPHTHALMOLOGY. 2006 JUL; 142 (1): 155-158   | 102 |



|     |  |     |
|-----|--|-----|
| 88  | 331 Gardner GG, Keating D, Williamson TH, Elliott AT<br>Automatic detection of diabetic retinopathy using an artificial neural network: A screening tool<br>BRITISH JOURNAL OF OPHTHALMOLOGY. 1996 NOV; 80 (11): 940-944   | 101 |
| 89  | 626 Hammes HP, Alt A, Niwa T, Clausen JT, Bretzel RG, et al.<br>Differential accumulation of advanced glycation end products in the course of diabetic retinopathy<br>DIABETOLOGIA. 1999 JUN; 42 (6): 728-736  | 101 |
| 90  | 641 Brown MM, Brown GC, Sharma S, Shah G<br>Utility values and diabetic retinopathy<br>AMERICAN JOURNAL OF OPHTHALMOLOGY. 1999 SEP; 128 (3): 324-330   | 101 |
| 91  | 1247 Klein BEK, Klein R, McBride PE, Cruickshanks KJ, Palta M, et al.<br>Cardiovascular disease, mortality, and retinal microvascular characteristics in type 1 diabetes - Wisconsin epidemiologic study of diabetic retinopathy<br>ARCHIVES OF INTERNAL MEDICINE. 2004 SEP 27; 164 (17): 1917-1924  | 101 |
| 92  | 956 Lin DY, Blumenkranz MS, Brothers RJ, Grosvenor DM<br>The sensitivity and specificity of single-field nonmydriatic monochromatic digital fundus photography with remote image interpretation for diabetic retinopathy screening: A comparison with ophthalmoscopy and standardized mydriatic color photography<br>AMERICAN JOURNAL OF OPHTHALMOLOGY. 2002 AUG; 134 (2): 204-213 | 100 |
| 93  | 1073 Tapp RJ, Shaw JE, Harper CA, de Courten MP, Balkau B, et al.<br>The prevalence of and factors associated with diabetic retinopathy in the Australian population<br>DIABETES CARE. 2003 JUN; 26 (6): 1731-1737   | 100 |
| 94  | 655 Fortune B, Schneck ME, Adams AJ<br>Multifocal electroretinogram delays reveal local retinal dysfunction in early diabetic retinopathy<br>INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE. 1999 OCT; 40 (11): 2638-2651  | 99  |
| 95  | 1021 Younis N, Broadbent DM, Vora JP, Harding SP<br>Incidence of sight-threatening retinopathy in patients with type 2 diabetes in the Liverpool Diabetic Eye Study: a cohort study<br>LANCET. 2003 JAN 18; 361 (9353): 195-200  | 99  |
| 96  | 459 Yu T, Mitchell P, Berry G, Li WN, Wang JJ<br>Retinopathy in older persons without diabetes and its relationship to hypertension<br>ARCHIVES OF OPHTHALMOLOGY. 1998 JAN; 116 (1): 83-89   | 98  |
| 97  | 707 Grant MB, Mames RN, Fitzgerald C, Hazariwala KM, Cooper-DeHoff R, et al.<br>The efficacy of octreotide in the therapy of severe nonproliferative and early proliferative diabetic retinopathy - A randomized controlled study<br>DIABETES CARE. 2000 APR; 23 (4): 504-509  | 98  |
| 98  | 799 Chaturvedi N, Sjoelie AK, Porta M, Aldington SJ, Fuller JH, et al.<br>Markers of insulin resistance are strong risk factors for retinopathy incidence in type 1 diabetes - The EURODIAB Prospective Complications Study<br>DIABETES CARE. 2001 FEB; 24 (2): 284-289  | 98  |
| 99  | 1502 Zhang SX, Wang JJ, Gao GQ, Parke K, Ma JX<br>Pigment epithelium-derived factor downregulates vascular endothelial growth factor (VEGF) expression and inhibits VEGF-VEGF receptor 2 binding in diabetic retinopathy<br>JOURNAL OF MOLECULAR ENDOCRINOLOGY. 2006 AUG; 37 (1): 1-12   | 98  |
| 100 | 494 Mitchell P, Smith W, Wang JJ, Attebo K<br>Prevalence of diabetic retinopathy in an older community - The Blue Mountains Eye Study<br>OPHTHALMOLOGY. 1998 MAR; 105 (3): 406-411   | 97  |

The numbers before the article indicate the location of the article on the histogram map.



## Appendix 2. Top Most Cited Articles (past 3 years)

|   | Date / Author / Journal  | GCS |
|---|--|-----|
| 1 | 206 Tang J, Kern TS<br>Inflammation in diabetic retinopathy<br>PROGRESS IN RETINAL AND EYE RESEARCH. 2011 SEP; 30 (5): 343-358   | 58  |
| 2 | 328 Yau JWY, Rogers SL, Kawasaki R, Lamoureux EL, Kowalski JW, et al.<br>Global Prevalence and Major Risk Factors of Diabetic Retinopathy<br>DIABETES CARE. 2012 MAR; 35 (3): 556-564                              | 56  |
| 3 | 49 Barber AJ, Gardner TW, Abcouwer SF<br>The Significance of Vascular and Neural Apoptosis to the Pathology of Diabetic Retinopathy<br>INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE. 2011 FEB; 52 (2): 1156-1163   | 50  |
| 4 | 23 Colagiuri S, Lee CMY, Wong TY, Balkau B, Shaw JE, et al.<br>Glycemic Thresholds for Diabetes-Specific Retinopathy Implications for diagnostic criteria for diabetes<br>DIABETES CARE. 2011 JAN; 34 (1): 145-150 | 42  |
| 5 | 81 McArthur K, Feng BA, Wu YX, Chen SL, Chakrabarti S<br>MicroRNA-200b Regulates Vascular Endothelial Growth Factor-Mediated Alterations in Diabetic Retinopathy<br>DIABETES. 2011 APR; 60 (4): 1314-1323          | 38  |
| 6 | 80 Zhong Q, Kowluru RA<br>Epigenetic Changes in Mitochondrial Superoxide Dismutase in the Retina and the Development of Diabetic Retinopathy<br>DIABETES. 2011 APR; 60 (4): 1304-1313                              | 31  |